NRC Health (NRC) Q3 2026 Earnings Call Transcript

NRC Health reported Q2 2026 revenue growth of approximately 4% year over year and TRCV growth of 11% to $151.9 million; its sales pipeline was up 60%, while adjusted EBITDA margin was 27%, flat sequentially and down 3 percentage points year over year. Management expects Q3 revenue to rise sequentially and EBITDA margin to improve in Q4, but said buyer uncertainty after the Qualtrics–Press Ganey acquisition has paused some procurement processes and average pipeline deal size is down. The company highlighted an AI-enabled rounding feature included in its current subscription and paid a $0.16-per-share quarterly dividend while repurchasing approximately 397,000 shares under its existing $1 million authorization.

Analysis

The investment case is conversion, not pipeline: stronger TRCV can support revenue as large deployments go live, but smaller average deal sizes and paused RFPs could dilute the quality and timing of that growth. The landmark rollout is a useful near-term execution test; the additional rounding product is not expected to start implementation until 2H27, so it should not be capitalized into the near-term thesis.

The Qualtrics–Press Ganey combination creates a two-sided effect. Near term, procurement uncertainty can delay NRC decisions and extend cash-conversion cycles. Over 6–18 months, integration complexity or customer dissatisfaction could make NRC’s established workflow a credible alternative—but that is a conditional opportunity, not yet evidence of share gains.

AI currently appears to be a retention and win-rate feature, not a distinct revenue stream. Treat margin benefits from internal automation as optionality until cost-to-serve or productivity data confirms them. Cross-sell is a substantial theoretical runway, but high single-product penetration is not proof of conversion; product connectivity and buyer access remain execution requirements.

Caution: the supplied material conflicts on reporting period and financial figures (including Q2 versus Q3), so verify the filed release before reacting to reported growth or modeling margins. No valuation evidence is provided to support a price target or an unconditional position.

Key Decisions for Investors

• Do not trade the headline figures until NRC’s filed results confirm the quarter, revenue, TRCV, free cash flow, and guidance; the source contains material internal inconsistencies.
• Keep NRC on a conditional long watchlist rather than chasing: seek evidence that the large deployment converts into reported revenue and that management delivers the guided Q4 margin improvement. Reassess if deployment milestones slip or margins fail to expand.
• Track RFP win rates, deal-size mix, sales-cycle duration, and customer additions over the next 1–3 months. Pipeline growth without improving conversion or deal economics would weaken the bullish read.
• Treat AI and cross-sell as unproven upside, not base-case earnings drivers. Upgrade conviction only with disclosed monetization, measurable retention or attach-rate gains, or demonstrable improvement in cost to serve.